A Trend in Acquired Drug Resistances of Tuberculosis Patients Registered in Health Centers from 1981 to 2004.
10.4046/trd.2005.59.6.619
- Author:
Chulhun L CHANG
1
;
Eun Yup LEE
;
Soon Kew PARK
;
Seok Hoon JEONG
;
Young Kil PARK
;
Yong Woon CHOI
;
Hee Jin KIM
;
Woo Jin LEW
;
Gill Han BAI
Author Information
1. Department of Laboratory Medicine, College of Medicine, Pusan National University, Busan, Korea.
- Publication Type:Original Article
- Keywords:
Tuberculosis;
Acquired drug resistance;
Multidrug resistance
- MeSH:
Compliance;
Drug Resistance;
Drug Resistance, Multiple;
Drug Therapy;
Ethambutol;
Humans;
Isoniazid;
Mycobacterium tuberculosis;
Pyrazinamide;
Rifampin;
Tuberculosis*
- From:Tuberculosis and Respiratory Diseases
2005;59(6):619-624
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: The drug resistance rate in tuberculosis patients with history of chemotherapy is an important indicator of for evaluation of appropriateness of treatment regimens and compliance of patients. This study examined the long-term changes in the drug resistance rates among TB patients failed in treatment or reactivated. METHODS: The results of drug susceptibility testing data from patients registered in health centers from 1981 to 2004 were analyzed. RESULTS: The rate of resistance to isoniazid decreased from 90% to 20%, and the resistance to ethambutol decreased from 45% to 6%. The rate of resistance to rifampicin varied from 13% to 28% and the resistance to pyrazinamide was 5% to 10%. Multidrug resistance was about 2-3% lower than any rifampicin resistance rates. The second-line drug resistance was ranged from 1% to 3%. There was no difference between patients' genders. Patient numbers per 100,000 population increased with age. The regional distribution was even at 4-6 patients per 100,000 population, and drug resistance rates were significantly lower in big city areas than in small towns and rural areas. CONCLUSION: The rates of resistance of Mycobacterium tuberculosis isolated from TB patients with history of chemotherapy to isoniazid, rifampin, ethambutol, and isoniazid plus rifampin were significantly decreased during over two decades.
